Drugs / Travatan Z
last change Nov 2024 re-read 3 minutes ago

Travatan Z

also known as travoprost
Developed for
glaucoma · eye adnexa disorder · ocular hypertension
Investigated by
Alcon Research · Pfizer · Wills Eye

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) TRAVATAN Z — 2010-08-31 fda.gov ↗
Approved US (FDA) TRAVATAN Z — 2006-09-21 fda.gov ↗

Trials 2

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 42 trials
Phase 4 NCT00798694 Nov 2008 → Jan 2011 glaucoma Wills Eye Completed No outcome recorded
Phase 4 NCT00468988 May → Jul 2007 glaucoma Alcon Research Completed No outcome recorded
Comparator or background therapy2 trials
Phase 2 NCT01254370 Comparator Nov 2010 → Jun 2011 eye adnexa disorder, glaucoma, ocular hypertension Santen SAS Completed No outcome recorded
Phase 4 NCT01937312 Background Oct 2013 → May 2014 ocular hypertension, open-angle glaucoma Alcon Research Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Travatan Z “dosed with TRAVATAN Z®, XALATAN®, or LUMIGAN®, 1 drop instilled in each eye once daily for 28 days” NCT01937312 ↗
3

NCT00468988 ↗

NCT00798694 ↗

NCT01254370 ↗

Known as travoprost “PURPOSE: To assess ocular surface changes in participants using latanoprost with benzalkonium chloride (Xalatan) and travoprost with SofZia (Travatan Z).” PMID 28617732 ↗ Nov 2018
Route Topical “one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime” NCT00798694 ↗